Boston Trust Walden Corp Sells 37,537 Shares of Charles River Laboratories International, Inc. $CRL

Key Points

• Boston Trust Walden cut its Charles River Laboratories stake by 13%, selling 37,537 shares in the third quarter and retaining 251,380 shares valued at about $74.2 million.
• Charles River reported quarterly earnings of $3.09 per share and revenue of $982.7 million, both above estimates, and raised its 2026 outlook. However, revenue declined 2.2% year over year.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $302.33; ratings range from one Strong Buy to one Sell.

Boston Trust Walden Corp reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 13.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 251,380 shares of the medical research company's stock after selling 37,537 shares during the quarter. Boston Trust Walden Corp owned 0.53% of Charles River Laboratories International worth $74,160,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in CRL. Physician Wealth Advisors Inc. increased its holdings in Charles River Laboratories International by 127.9% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company's stock worth $29,000 after purchasing an additional 55 shares in the last quarter. Continuum Advisory LLC bought a new stake in shares of Charles River Laboratories International in the second quarter valued at about $30,000. IFP Advisors Inc lifted its holdings in shares of Charles River Laboratories International by 182.8% in the third quarter. IFP Advisors Inc now owns 164 shares of the medical research company's stock valued at $48,000 after purchasing an additional 106 shares in the last quarter. Compass Wealth Management LLC bought a new stake in shares of Charles River Laboratories International in the third quarter valued at about $69,000. Finally, Activest Wealth Management boosted its position in shares of Charles River Laboratories International by 25.9% during the third quarter. Activest Wealth Management now owns 277 shares of the medical research company's stock worth $82,000 after buying an additional 57 shares during the period. 98.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Evercore set a $330.00 price objective on Charles River Laboratories International in a report on Friday, September 25th. Jefferies Financial Group lifted their target price on Charles River Laboratories International from $305.00 to $340.00 and gave the company a "buy" rating in a research report on Monday, September 28th. Zacks Research downgraded Charles River Laboratories International from a "strong-buy" rating to a "hold" rating in a research report on Monday. UBS Group began coverage on shares of Charles River Laboratories International in a research note on Wednesday, September 30th. They set a "buy" rating and a $357.00 price target for the company. Finally, Mizuho raised their price target on shares of Charles River Laboratories International from $264.00 to $295.00 and gave the stock a "neutral" rating in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Charles River Laboratories International has a consensus rating of "Moderate Buy" and a consensus price target of $302.33.

More Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Third-quarter adjusted earnings were $3.09 per share, above estimates of about $2.97, and revenue of $982.7 million beat expectations of roughly $960.4 million. Organic growth and margin expansion supported results, and the company lifted its 2026 outlook. Charles River Q3 Earnings & Revenues Top Estimates, Stock Rises
• Negative Sentiment: Despite beating estimates, revenue was down 2.2% from the same quarter last year, a possible concern for investors weighing the strong quarterly beat. Charles River Laboratories Announces Third-Quarter 2026 Results
• Negative Sentiment: Zacks Research lowered its rating on CRL from “strong-buy” to “hold,” which may have added pressure. The available reports note that shares fell despite the earnings beat and raised outlook, but do not give a definitive explanation for the market reaction. Zacks Research rating information

Insider Activity

In related news, Director James C. Foster sold 33,561 shares of the firm's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total value of $10,068,300.00. Following the completion of the transaction, the director directly owned 31,596 shares of the company's stock, valued at approximately $9,478,800. This trade represents a 51.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Birgit Girshick sold 6,500 shares of the business's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the transaction, the chief executive officer owned 36,013 shares in the company, valued at approximately $10,080,038.70. The trade was a 15.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 102,299 shares of company stock valued at $31,050,863 over the last three months. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Performance

CRL opened at $326.62 on Thursday. The business's 50-day simple moving average is $304.55 and its 200 day simple moving average is $224.12. Charles River Laboratories International, Inc. has a 52-week low of $146.20 and a 52-week high of $379.63. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The firm has a market capitalization of $15.59 billion, a PE ratio of -67.34, a PEG ratio of 3.29 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, beating analysts' consensus estimates of $2.97 by $0.12. The firm had revenue of $982.73 million during the quarter, compared to the consensus estimate of $960.36 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The business's revenue was down 2.2% compared to the same quarter last year. During the same period last year, the company earned $2.43 earnings per share. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.38 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.